Illustration of a cell with an imbalanced endoplasmic reticulum (ER) network due to a mutated GNE gene, symbolizing disrupted protein folding and cellular imbalance.

Unlocking the Secrets of GNE Myopathy: How a Gene Mutation Impacts Cellular Health

Author's portrait.
Kai Mendoza in Health & Wellness June 2025 • 5 min read.

"New research reveals how a mutation in the GNE gene disrupts the delicate balance of cellular processes, offering potential therapeutic targets."


GNE myopathy, a rare and debilitating neuromuscular disorder, is characterized by muscle weakness and atrophy that typically begin in early adulthood. The root cause of this condition lies in mutations within the GNE (UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) gene, an essential player in the body's ability to produce sialic acid. Sialic acid is a crucial building block for glycoproteins, molecules that are vital for cell communication, immune responses, and maintaining tissue structure.

While scientists have long known that GNE myopathy involves reduced levels of sialic acid, the precise mechanisms by which these mutations lead to muscle damage have remained elusive. Over 180 different GNE mutations have been identified worldwide, each potentially impacting cellular functions in subtle yet significant ways. Understanding these nuances is key to developing targeted therapies that can effectively combat the disease.

A recent study published in Neuromolecular Medicine has delved deeper into this mystery. Researchers investigated how mutant GNE proteins affect cellular processes beyond sialic acid production. Their findings reveal a surprising connection between GNE mutations and the disruption of redox homeostasis, a delicate balance of oxidation and reduction reactions that is essential for cell survival. This breakthrough offers new avenues for understanding the disease's progression and potentially identifying novel therapeutic targets.

How Does a GNE Mutation Lead to Cellular Imbalance?

Illustration of a cell with an imbalanced endoplasmic reticulum (ER) network due to a mutated GNE gene, symbolizing disrupted protein folding and cellular imbalance.

The research team focused on the impact of mutant GNE proteins on cellular functions by analyzing the proteome profile of HEK293 cells. They compared cells overexpressing normal GNE protein with those expressing two pathologically relevant mutant forms of the protein (D207V and V603L). These cell lines serve as a model to mimic the effects of GNE mutations seen in patients with GNE myopathy. By examining the cells' protein composition, the researchers aimed to identify key differences that could explain the disease's development.

Using two-dimensional gel electrophoresis coupled with mass spectrometry, the researchers identified ten proteins that were differentially expressed in cells with mutant GNE compared to those with normal GNE. One protein that stood out was peroxiredoxin IV (PrdxIV), an antioxidant enzyme residing in the endoplasmic reticulum (ER). The ER is a critical organelle responsible for protein folding and quality control within the cell.

  • PrdxIV's Role: PrdxIV acts as a sensor of hydrogen peroxide (H2O2), a reactive oxygen species (ROS) produced during protein folding. It helps regulate neurogenesis and maintain a healthy cellular environment.
  • The Findings: The study revealed that PrdxIV was downregulated in cells expressing mutant GNE, suggesting that the mutation disrupts the normal antioxidant defense mechanisms within the ER.
  • Additional Dysregulation: Further analysis confirmed that both mRNA and protein levels of PrdxIV were significantly reduced in GNE mutant cell lines.
While the study didn't find any alterations in total reactive oxygen species or H2O2 accumulation in the mutant cells, they discovered that the ER's redox state was significantly affected. This imbalance suggests that the reduced normal GNE enzyme activity indirectly impacts the ER environment, potentially leading to protein misfolding and aggregation. These are hallmarks of GNE myopathy.

What Does This Mean for Potential Treatments?

This research suggests that targeting the ER redox state and PrdxIV levels could offer a novel therapeutic approach for GNE myopathy. By restoring the delicate balance within the ER, it may be possible to reduce protein misfolding and aggregation, ultimately slowing down or preventing the progression of the disease. Further research is needed to fully elucidate the mechanisms involved and to develop effective therapies that can translate these findings into clinical benefits for patients with GNE myopathy.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is GNE myopathy, and what causes it?

GNE myopathy is a rare neuromuscular disorder characterized by muscle weakness and atrophy, typically appearing in early adulthood. It is caused by mutations in the GNE gene, which is responsible for producing the enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. This enzyme is essential for producing sialic acid, a crucial building block for glycoproteins that are vital for cell communication, immune responses, and maintaining tissue structure. Over 180 different GNE mutations have been identified, each impacting cellular functions in subtle ways.

2

How does a mutation in the GNE gene affect cellular processes?

A GNE mutation disrupts the delicate balance of cellular processes. It primarily affects the production of sialic acid, a critical component of glycoproteins, impacting cell communication, immune responses, and tissue structure. Furthermore, the mutation has been shown to disrupt redox homeostasis within the endoplasmic reticulum (ER). This leads to an imbalance in oxidation and reduction reactions, which is essential for cell survival, and it may lead to protein misfolding and aggregation.

3

What role does the protein PrdxIV play in the context of GNE myopathy?

PrdxIV, an antioxidant enzyme residing in the endoplasmic reticulum (ER), is downregulated in cells expressing mutant GNE. PrdxIV acts as a sensor of hydrogen peroxide (H2O2), a reactive oxygen species (ROS) produced during protein folding. It helps regulate neurogenesis and maintain a healthy cellular environment. The downregulation of PrdxIV in GNE mutant cells disrupts the normal antioxidant defense mechanisms within the ER. This ER redox imbalance can contribute to protein misfolding and aggregation, which are hallmarks of GNE myopathy.

4

What is the significance of the endoplasmic reticulum (ER) in GNE myopathy?

The endoplasmic reticulum (ER) is a critical organelle responsible for protein folding and quality control within the cell. The ER's redox state is significantly affected by GNE mutations. The study revealed that the ER environment is indirectly impacted by the reduced normal GNE enzyme activity, potentially leading to protein misfolding and aggregation. This suggests that targeting the ER redox state could be a novel therapeutic approach for GNE myopathy, as restoring the delicate balance within the ER may reduce protein misfolding and aggregation, potentially slowing or preventing disease progression.

5

What potential treatment strategies emerge from the recent research on GNE myopathy?

The research suggests that targeting the ER redox state and PrdxIV levels could offer a novel therapeutic approach for GNE myopathy. The findings indicate that restoring the balance within the ER, which is disrupted by the GNE mutation, may help to reduce protein misfolding and aggregation, ultimately slowing the disease's progression. Further research is necessary to fully understand the mechanisms involved and to develop effective therapies, potentially translating these findings into clinical benefits for patients with GNE myopathy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.